Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2618384 | 0.85 | BRD4 (0.49) | PTGDR2RORCALDH1A1KMT2APTGS2 | |
| SCHEMBL2602440 | 0.79 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL2607566 | 0.78 | CYP1A2 (0.49) | PTGDR2RORCMEN1ALDH1A1KMT2A | |
| SCHEMBL3439934 | 0.74 | TP53 (0.51) | RORCMEN1ALDH1A1KMT2APTGS2 | |
| SCHEMBL2618383 | 0.74 | BRD4 (0.53) | MEN1ALDH1A1KMT2APTGS2POLB | |
| SCHEMBL2602444 | 0.73 | MAPK8 (0.43) | MEN1KMT2APTGS2 | |
| SCHEMBL2602443 | 0.70 | PTGS2 (0.47) | ALDH1A1PTGS2PTGS1 | |
| SCHEMBL2602426 | 0.68 | CA1 (0.53) | PTGS2PTGS1 | |
| SCHEMBL2618378 | 0.68 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL2602439 | 0.68 | PTGS2 (0.42) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362019-B2 | Synthesis and anti-proliferative effect of substituted imidazo[4,5-b]pyrazine compounds | SPELMAN COLLEGE (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120095009-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | SPELMAN COLLEGE (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095009-A1 | SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES | MKI67, CCNI, TYMP | PTGDR2 1842/4885RORC 1370/4885MEN1 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.